ClinicalTrials.gg
WithdrawnNCT05482282Updated Jun 5, 2025

Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

A Phase 3 interventional study of Recombinant Hepatitis B new Bulk vaccine and DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine in Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction and Pertussis Vaccine Adverse Reaction, sponsored by PT Bio Farma. Withdrawn at 3 sites in Indonesia. Open to participants aged 1 Day to 3 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by PT Bio Farma · Phase 3, Interventional, and Prevention

Why this study was withdrawn
The products will be replace with others.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
1 Day to 3 Days
Sex
All
01

Study summary

This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma).

Read the detailed description

This bridging study is a randomized, double blind, two arms parallel groups, prospective intervention study. Total 220 infants, 0-3 days old will be involved in this study. The subject will be divided into 2 groups, 110 subjects are the investigational group and 110 subjects are the active comparator group.

The objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma) and to asses the safety of DTP-HB-Hib Vaccine (Bio Farma) and Recombinant Hepatitis B Vaccine using new Hepatitis B bulk (Bio Farma).

02

Conditions studied

  • Diphtheria Vaccine Adverse Reaction
  • Tetanus Vaccine Adverse Reaction
  • Pertussis Vaccine Adverse Reaction
  • Haemophilus Influenzae Type B Vaccine Adverse Reaction
  • Hepatitis B Vaccine Adverse Reaction

Browse trials for

Keywords

  • DTP-HB-Hib Vaccine
  • Hepatitis B Vaccine
03

In context

Hepatitis B

1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 3 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, full term, newborns infants.
  2. Infant born after 37-42 weeks of pregnancy.
  3. Infant weighing 2500 gram or more at birth.
  4. Father, mother or legally acceptable representative properly informed about the study and having signed the form.
  5. Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Child concomitantly enrolled or scheduled to be enrolled in another trial.
  2. Child evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature 37.5 celcius degrees on Day 0).
  3. Child suspected of allergy to any component of the vaccines (e.g. formaldehyde), based on anamnesis.
  4. Child suspected of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection, based on anamnesis
  5. Newborn suspected of congenital or acquired immunodeficiency, based on anamnesis
  6. Child received or plans to receive any treatment likely to alter the immune response intravenous (immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks)).
  7. Child received other vaccination with the exception of BCG and poliomyelitis.
  8. Child has any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
  9. Mother with HbsAg and positive (by rapid test within 30 days prior subject's birth)
  10. Mother suspected of immunodeficiency disease based on anamnesis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Recombinant Hep B new Bulk + Penta with Recombinant HepB new Bulk

    1 dose Recombinant Hepatitis B new Bulk vaccine at birth + 3 doses Pentavalent with Recombinant HepB new Bulk vaccine

    Biological: Recombinant Hepatitis B new Bulk vaccine · Biological: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine

  • Active comparator
    Hep B (Registered) + Pentabio (Registered)

    1 dose Recombinant Hepatitis B vaccine (Registered) + 3 doses Pentabio with Recombinant HepB new Bulk vaccine

    Biological: Recombinant Hepatitis B vaccine (Registered BioFarma) · Biological: Pentabio

Interventions

  • BiologicalRecombinant Hepatitis B new Bulk vaccine

    1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma) 1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region.

  • BiologicalDTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine

    3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine

  • BiologicalRecombinant Hepatitis B vaccine (Registered BioFarma)

    1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)

  • BiologicalPentabio

    3 doses of Pentabio

06

What researchers measure

Primary outcomes

  1. To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma)

    Percentage of infants with anti-diphtheria titer and anti-tetanus titer more than 0.01 IU/ml, anti HbsAg titer more than 10 mIU/ml, and anti PRP-TT titer more than 0.15 microgram/ml 28 days after the last injection of DTP-HB-Hib using new Hepatitis B bulk (Bio Farma) vaccine group.

    Time frame: 28 days

Secondary outcomes

  1. To asses the local and systemic reactions within 30 minutes

    Local reaction and systemic events occurring within 30 minutes after immunization.

    Time frame: 30 minutes

  2. To asses the local and systemic reactions within 30 minutes to 7 days after immunization

    Local reaction and systemic events occurring after 30 minutes to 7 days after immunization.

    Time frame: 7 days

  3. To asses the local and systemic reactions within 7 days to 28 days after immunization

    Local reaction and systemic events occurring after 7 days to 28 days following the vaccination.

    Time frame: 28 days

  4. To asses the serious adverse event

    Any serious adverse event occuring from inclusion until 28 days after the last dose

    Time frame: 28 days

07

Study locations

3 sites
  • Garuda Primary Health Centre
    Bandung, West Java, Indonesia
  • Ibrahim Adjie Primary Health Centre
    Bandung, West Java, Indonesia
  • Puter Primary Health Centre
    Bandung, West Java, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2022
First posted
Aug 1, 2022
StartEst.
Dec 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05482282
Lead sponsor
PT Bio Farma
Collaborators
Hasan Sadikin General Hospital
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Dec 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 5, 2025

Study contacts

Eddy Fadlyana, MD
principal investigator · Hasan Sadikin General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion